Vascular Endothelial Growth Factor A

"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.

Descriptor ID	D042461
MeSH Number(s)	D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
Concept/Terms	Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor-A VEGF-A Vasculotropin VEGF Vascular Endothelial Growth Factor Vascular Permeability Factor Permeability Factor, Vascular Glioma-Derived Vascular Endothelial Cell Growth Factor Glioma-Derived Vascular Endothelial Cell Growth Factor Glioma Derived Vascular Endothelial Cell Growth Factor GD-VEGF

Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intercellular Signaling Peptides and Proteins [D12.644.276]
Angiogenic Proteins [D12.644.276.100]
Vascular Endothelial Growth Factors [D12.644.276.100.800]
Vascular Endothelial Growth Factor A [D12.644.276.100.800.200]
Proteins [D12.776]
Intercellular Signaling Peptides and Proteins [D12.776.467]
Angiogenic Proteins [D12.776.467.100]
Vascular Endothelial Growth Factors [D12.776.467.100.800]
Vascular Endothelial Growth Factor A [D12.776.467.100.800.200]
Biological Factors [D23]
Intercellular Signaling Peptides and Proteins [D23.529]
Angiogenic Proteins [D23.529.100]
Vascular Endothelial Growth Factors [D23.529.100.800]
Vascular Endothelial Growth Factor A [D23.529.100.800.200]

Below are MeSH descriptors whose meaning is related to "Vascular Endothelial Growth Factor A".

Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.

Bar chart showing 127 publications over 25 distinct years, with a maximum of 13 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	2	2
1999	0	1	1
2001	0	2	2
2002	0	6	6
2003	1	3	4
2004	4	3	7
2005	4	3	7
2006	2	2	4
2007	0	3	3
2008	6	3	9
2009	3	4	7
2010	5	2	7
2011	4	5	9
2012	4	6	10
2013	5	1	6
2014	4	3	7
2015	1	1	2
2016	4	9	13
2017	1	3	4
2018	2	3	5
2019	2	2	4
2020	0	1	1
2021	1	2	3
2022	1	0	1
2023	1	2	3

Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.

Zhu X, Gebo KA, Abraham AG, Habtehyimer F, Patel EU, Laeyendecker O, Gniadek TJ, Fernandez RE, Baker OR, Ram M, Cachay ER, Currier JS, Fukuta Y, Gerber JM, Heath SL, Meisenberg B, Huaman MA, Levine AC, Shenoy A, Anjan S, Blair JE, Cruser D, Forthal DN, Hammitt LL, Kassaye S, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Abinante M, Broderick P, Cluzet V, Cordisco ME, Greenblatt B, Petrini J, Rausch W, Shade D, Lane K, Gawad AL, Klein SL, Pekosz A, Shoham S, Casadevall A, Bloch EM, Hanley D, Sullivan DJ, Tobian AAR. Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study. Lancet Microbe. 2023 09; 4(9):e692-e703.

View in: PubMed
Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, Zhu LJ, Li R, St Louis PA, Ferreira LM, Pakula H, Xu Z, Loda M, Jiang Z, Brehm MA, Mercurio AM. Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Sci Transl Med. 2023 05 03; 15(694):eade5855.

View in: PubMed
Xu Z, Goel HL, Burkart C, Burman L, Chong YE, Barber AG, Geng Y, Zhai L, Wang M, Kumar A, Menefee A, Polizzi C, Eide L, Rauch K, Rahman J, Hamel K, Fogassy Z, Klopp-Savino S, Paz S, Zhang M, Cubitt A, Nangle LA, Mercurio AM. Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer. Sci Transl Med. 2023 05 03; 15(694):eadf1128.

View in: PubMed
Santoni M, Molina-Cerrillo J, Myint ZW, Massari F, Buchler T, Buti S, Matrana MR, De Giorgi U, Rizzo M, Zabalza IO, Galli L, Zucali PA, Aurilio G, Incorvaia L, Bassanelli M, Mammone G, Salfi A, Isella L, Mollica V, Grande E, Porta C, Battelli N. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies. Target Oncol. 2022 09; 17(5):571-581.

View in: PubMed
Eleftheriadou D, Berg M, Phillips JB, Shipley RJ. A combined experimental and computational framework to evaluate the behavior of therapeutic cells for peripheral nerve regeneration. Biotechnol Bioeng. 2022 07; 119(7):1980-1996.

View in: PubMed
Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, Fahr N, Desbuisson M, Grimm A, Zhang H, Chong C, Dagher J, Chee S, Tsianou T, Dorier J, Stevenson BJ, Iseli C, Ronet C, Bobisse S, Genolet R, Walton J, Bassani-Sternberg M, Kandalaft LE, Ren B, McNeish I, Swisher E, Harari A, Delorenzi M, Ciriello G, Irving M, Rusakiewicz S, Foukas PG, Martinon F, Dangaj Laniti D, Coukos G. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Rep. 2021 07 20; 36(3):109412.

View in: PubMed
Cheng SY, Luo Y, Malachi A, Ko J, Su Q, Xie J, Tian B, Lin H, Ke X, Zheng Q, Tai PWL, Gao G, Punzo C. Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis. Hum Gene Ther. 2021 07; 32(13-14):649-666.

View in: PubMed
Cheng SY, Punzo C. Ocular Inflammation with Anti-Vascular Endothelial Growth Factor Treatments. Hum Gene Ther. 2021 Jul; 32(13-14):639-641.

View in: PubMed
Bressler NM, Beaulieu WT, Bressler SB, Glassman AR, Melia BM, Jampol LM, Jhaveri CD, Salehi-Had H, Velez G, Sun JK. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials. Retina. 2020 Jun; 40(6):1021-1028.

View in: PubMed
Merle BMJ, Rosner B, Seddon JM. Genetic Susceptibility, Diet Quality, and Two-Step Progression in Drusen Size. Invest Ophthalmol Vis Sci. 2020 05 11; 61(5):17.

View in: PubMed

People

Explore

Similar Concepts

Top Journals